Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

While there continues to be a trickle of acquisitions — including AstraZeneca’s recent $1bn bid for EsoBiotec — big pharma has largely focused on licensing deals, often with Chinese biotechs. These ...